EU Regulation 2017/746 (IVDR) fundamentally changed the regulatory landscape for in vitro diagnostic medical devices — bringing far stricter requirements, a new risk classification system, and mandatory Notified Body involvement for most device classes. This guide explains what you need to know.
EU Regulation 2017/746 (IVDR) is the European regulation governing in vitro diagnostic medical devices — products used to examine samples taken from the human body, such as blood, urine, or tissue, in order to provide information about physiological or pathological states.
IVDR replaced the former IVD Directive (98/79/EC, IVDD) and introduced significantly more demanding requirements, particularly around performance evaluation, clinical evidence, and Notified Body involvement. The regulation became fully applicable on 26 May 2022, with transitional arrangements for legacy devices.
IVDR introduces a four-class risk-based classification system (A, B, C, D), replacing the IVDD's simpler list-based approach:
Lowest risk. General laboratory instruments, buffers, specimen receptacles (non-sterile). Self-declaration permitted.
Low-moderate risk. Devices not classified as A, C, or D. Notified Body required.
Moderate-high risk. Blood grouping, HLA typing, HCV/HIV/HBV detection, tumour markers, certain companion diagnostics. NB required.
Highest risk. Detection of life-threatening transmissible agents: HIV, HBV, HCV, HTLV, Treponema pallidum, blood safety screening. NB required.
Classification rules are set out in IVDR Annex VIII. Unlike MDR for medical devices, IVDR classification is based on intended purpose and risk — not just the physical characteristics of the device.
The requirement for Notified Body involvement under IVDR is dramatically broader than under the IVDD:
This represents a massive change from IVDD, where only devices on the IVDD Annex II list required NB involvement. Under IVDR, all Class B, C, and D devices — which represent the majority of IVDs — require an NB.
One of the most significant changes under IVDR is the requirement for performance evaluation — the equivalent of clinical evaluation under MDR. Manufacturers must demonstrate that their IVD devices achieve the intended purpose based on clinical and/or scientific evidence.
IVDR Annex XIII defines the performance evaluation requirements. Performance evaluation encompasses:
For Class C and D devices, the performance evaluation report must be particularly robust, based on clinical performance studies and/or peer-reviewed published data.
Class D devices face an additional requirement unique to IVDR: EU Reference Laboratories (EURLs). These are designated laboratories that verify the performance claims of Class D devices and conduct batch release testing.
The Notified Body must obtain an opinion from the relevant EURL before issuing a certificate for a Class D device. This process adds significant time to the Class D certification pathway — plan for 6–12 months additional to the standard NB timeline.
The European Commission has the authority to publish Common Specifications (CS) for IVDR devices — similar to those for MDR Annex XVI products. Common Specifications define minimum performance, safety, and performance evaluation requirements for specific device types.
For devices covered by a CS, compliance with the CS is mandatory. Manufacturers must check whether a CS exists for their device type and incorporate its requirements into their technical documentation.
| Device Class | Transition Deadline | Conditions |
|---|---|---|
| Class D (legacy) | 26 May 2025 | Valid IVDD certificate OR no IVDD certificate required; application to NB submitted before 26 May 2022 |
| Class C (legacy) | 26 May 2026 | Same conditions as above |
| Class B and Class A sterile (legacy) | 26 May 2027 | Same conditions as above |
These transition deadlines apply to devices already on the market under IVDD. New devices not previously placed on the market must comply with IVDR from the moment of first placement. Verify your specific situation with a regulatory consultant — the transitional provisions are complex and subject to updated guidance.
Similar to MDR, IVDR requires comprehensive technical documentation covering:
Non-EU manufacturers of IVDs must appoint an EU Authorised Representative under IVDR Article 11 — in exactly the same way as MDR device manufacturers. The AR must be established in the EU, is named on the label, and is registered in EUDAMED.
→ See full guide: EU Authorized Representative Under MDR | EAR Services Guide
ECP connects IVD manufacturers with regulatory consultants, Notified Bodies, and EU Authorised Representatives who specialise in IVDR. Submit your request and receive structured proposals.
Submit a Request — Free